Skip to main content
. 2008 Sep;9(6):381–393. doi: 10.2174/138920208785699553

Fig. (2).

Fig. (2)

Molecular mechanism of biologic therapies: A) The tumor necrosis factor-α (TNF-α) blocker, Etanercept. B) The tumor necrosis factor-α (TNF-α) blocker, Infliximab. C) The tumor necrosis factor-α (TNF-α) blocker, Adalimumab. D) The interleukin-1 (IL-1) blocker, Anakinra, a recombinant form of the human IL-1 receptor antagonist (IL-1RA).